Compare Adobe Systems Inc (ADBE) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adobe Systems Inc vs Merck & Co., Inc. — how do they compare? Adobe Systems Inc trades at $258.74 (market cap $104.82B), while Merck & Co., Inc. trades at $129.69 (market cap $321.77B). The key difference: Merck & Co., Inc. is far larger — about 3.1× Adobe Systems Inc's market cap, and Merck & Co., Inc. pays a 2.61% dividend while Adobe Systems Inc pays none. Which is the better fit depends on your goals.
| ADBE | MRK | |
|---|---|---|
Market Cap | $104.82B | $321.77B |
Volume | 5,187,646 | — |
Sector | Technology | Health |
52-Week High | $367.46 | $131.84 |
52-Week Low | $193.41 | $77.60 |
Enterprise Value | $106.26B | $368.53B |
Dividend Yield | — | 2.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Adobe (ADBE) trades at $272.96, up 2.92% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with 2025 revenue of $23.77B and net income of $7.13B, maintaining exceptional profitability margins. Recent earnings beats and accelerating revenue growth contrast with market concerns about AI competition and CEO transition.
Adobe presents a compelling value opportunity trading below analyst consensus targets despite strong operational performance. Key risks include AI disruption threats and ongoing leadership transition, while institutional accumulation and positive earnings momentum support potential upside. The stock's current valuation multiples appear attractive relative to growth prospects.
Merck (MRK) trades at $130.9, up 1.81% today, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $140.36. Recent earnings beats and a 72.97% gross margin highlight strong profitability, while the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline. The stock faces headwinds from a high P/E ratio of 104.34 and fluctuating cash flows.
The outlook is positive with robust fundamentals and strategic M&A, but valuation concerns and competitive pressures in pharma pose risks. Upside is likely if earnings growth continues, though investors should monitor debt levels and integration of acquisitions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adobe Systems Inc
Adobe Inc. develops, markets, and supports computer software products and technologies. The Company's products allow users to express and use information across all print and electronic media. Adobe offers a line of application software products, type products, and content for creating, distributing, and managing information.
Read more on ADBE →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
